EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Pharmacokinetics and Bioequivalence of Ilaprazole Enteric‐Coated Tablets in Healthy Chinese Volunteers: A Two‐Sequence, Four‐Period, Fully Replicated Crossover Study

Lijie Du, Yi Zhang, Fangliang Gan, Jiamin Yang, Li Li

Clinical Pharmacology in Drug Development · 2025

DOI: 10.1002/cpdd.1628 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Lijie Du und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Hubei University of Science and Technology, Xianning, China. Hauptthemen laut MEDLINE: Proton Pump Inhibitors, 2-Pyridinylmethylsulfinylbenzimidazoles. Die Arbeit nennt 14 Literaturangaben. Gefördert von: Ningbo Ke'erkang Menovo Pharmaceutical Co., Ltd., Ningbo Menovo Tiankang Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ilaprazole enteric‐coated tablets are a novel proton pump inhibitor primarily used for the treatment of gastroesophageal reflux disease, with metabolism not affected by CYP2C19 genetic polymorphism. This study evaluated the pharmacokinetics and bioequivalence of two formulations of ilaprazole enteric‐coated tablets in Chinese healthy volunteers under fasting and fed conditions using a single‐center, randomized, open‐label, single‐dose, two‐formulation, four‐period, two‐sequence, fully replicated crossover design. A total of 72 volunteers were enrolled, with 36 in each group. In the fasting group, volunteers received a single dose of 5 mg of the test or reference formulation in each period, while in the fed group, a high‐fat meal was consumed 30 min before drug administration. Blood samples were collected within 36 h postdose, and plasma concentrations of ilaprazole were analyzed using ultra‐performance liquid chromatography‐tandem mass spectrometry. The geometric means and 90% confidence intervals of AUC 0–t , AUC 0–∞ , and C max for both fasting and fed conditions were within the 80%–125% bioequivalence range, and the upper limit of the one‐sided 95% confidence interval was ≤0. Both formulations demonstrated bioequivalence under these conditions, with no serious adverse reactions observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proton Pump Inhibitors2-PyridinylmethylsulfinylbenzimidazolesHumansCross-Over StudiesTherapeutic EquivalencyMaleAdultTablets, Enteric-CoatedYoung AdultHealthy VolunteersArea Under CurveFemaleFastingAsian PeopleFood-Drug InteractionsChinaTandem Mass Spectrometry

Stichwörter der Autor:innen

bioequivalenceenteric‐coated tabletilaprazolepharmacokineticssafety

Substanzen

ilaprazoleTablets, Enteric-CoatedProton Pump Inhibitors2-Pyridinylmethylsulfinylbenzimidazoles

Autor:innen und Institutionen

  • School of Pharmacy, Hubei University of Science and Technology, Xianning, China.
  • Phase I Clinical Research Center, The First Affiliated Hospital of Hubei University of Science and Technology, Xianning Central Hospital, Xianning, China.

Förderung

  • Ningbo Ke'erkang Menovo Pharmaceutical Co., Ltd.
  • Ningbo Menovo Tiankang Pharmaceutical Co., Ltd.

Zitieren

APA

Du, L., Zhang, Y., Gan, F., Yang, J., & Li, L. (2025). Pharmacokinetics and Bioequivalence of Ilaprazole Enteric‐Coated Tablets in Healthy Chinese Volunteers: A Two‐Sequence, Four‐Period, Fully Replicated Crossover Study. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1628

Vancouver

Du L, Zhang Y, Gan F, Yang J, Li L. Pharmacokinetics and Bioequivalence of Ilaprazole Enteric‐Coated Tablets in Healthy Chinese Volunteers: A Two‐Sequence, Four‐Period, Fully Replicated Crossover Study. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1628

BibTeX
@article{Du2025,
  author = {Du, Lijie and Zhang, Yi and Gan, Fangliang and Yang, Jiamin and Li, Li},
  title = {Pharmacokinetics and Bioequivalence of Ilaprazole Enteric‐Coated Tablets in Healthy Chinese Volunteers: A Two‐Sequence, Four‐Period, Fully Replicated Crossover Study},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2025},
  doi = {10.1002/cpdd.1628}
}
Kostenlos starten →